Skip to content

Investors

Building towardclinical validation.

Object Pharma is advancing OP01 toward clinical development while building a differentiated neurotoxin platform designed to create multiple therapeutic opportunities.

Investor resources

Corporate presentation

The current corporate presentation and investor materials are available to qualified parties on request.

Request Investor Information